Scott Gottlieb is a physician and served as the 23rd Commissioner of the U.S. Food and Drug Administration. Dr. Gottlieb’s work focuses on advancing public health through developing and implementing innovative approaches to improving medical outcomes, reshaping healthcare delivery, and expanding consumer choice and safety. He serves on the boards of Pfizer Inc. and Illumina, Inc., is a resident fellow at the American Enterprise Institute and a partner at the venture capital firm New Enterprise Associates.
Dr. Gottlieb is an aggressive advocate for advancing the health of patients, promoting healthcare access, and driving innovation. The agency’s historic and prolific advances in new policy distinguished his tenure as the FDA’s commissioner, in addition to a record-setting number of approvals of novel drugs, medical devices, and generic medicines. Under his leadership, the FDA advanced new frameworks for the modern and safe and effective oversight of gene therapies, cell based regenerative medicines, targeted drugs, and digital health devices. The FDA implemented new reforms to standardize drug reviews and make historic improvements of post market data collection and the use of real-world evidence. They promoted policies to reduce death and disease from tobacco, improve food safety, and aggressively confront addiction crises.
Previously, Dr. Gottlieb served as the FDA’s Deputy Commissioner for Medical and Scientific Affairs and before that, as a Senior Adviser to the Administrator of the Centers for Medicare and Medicaid Services, where he helped advance policies to improve healthcare quality and promote the effective use of new medical technologies. Dr. Gottlieb is widely published in leading medical journals and periodicals, including The Wall Street Journal, The New York Times, and The Washington Post. He has held editorial positions on the British Medical Journal and the Journal of the American Medical Association and is a regular contributor to CNBC. Fortune Magazine recognized him as one of the “World’s 50 Greatest Leaders” in 2018 and again in 2019. In 2018 and then again in 2019 Modern Healthcare named Dr. Gottlieb the “Most Influential Physician Executive and Leaders” in its annual survey of 50 physician executives, and Time magazine named him one of its “50 People Transforming Healthcare in 2018.” Dr. Gottlieb was a practicing hospitalist and he is an elected member of the National Academy of Medicine. He lives in Westport, Connecticut with his wife and three daughters.
Dr. Amy Zalman
is the founder and CEO of Prescient
, a foresight consultancy that helps Fortune 500 firms, governments and non-profit organizations to anticipate and prepare for the future. She is a professor of strategic foresight in the Culture, Communications & Technology Program at Georgetown University, and the founder and director of the Foresight Sandbox, a collaboration with Arizona State University’s School for the Future of Innovation in Society to provide strategic foresight training to business and government leaders. Huffington Post called her one of the world’s seven top futurists in 2015, and she was cited in Forbes as one of the world’s 50 leading female futurists in 2020.
Dr. Zalman’s previous roles include Chief Executive Officer and President of the World Future Society, and the Chair of Information Integration at the U.S. National War College. She earned her doctorate from the Department of Middle Eastern & Islamic Studies at New York University.
Media journalist, radio and podcast host, and published author Bob Garfield will present highlights from his new book, American Manifesto: Saving Democracy from Villains, Vandals, and Ourselves, and will lead a focused discussion on the polarization of media.
Christopher Boone, PhD has a career-long history as a dynamic, innovative thought leader and a public voice on the power of real-world evidence, health informatics, and big data analytics and its ability to radically transform the global health care system into a learning health system.
Chris currently serves as the Vice President, Global Head of Health Economics and Outcomes Research at Abbvie. He is also an adjunct assistant professor of health administration at the New York University's Robert F. Wagner Graduate School of Public Service, an active board member of several influential organizations, and a co-founder of a few start-up companies. Most recently, he served as the vice president and head of global medical epidemiology and big data analysis at Pfizer.
Chris has been recognized as a 2019 Top 100 Innovator in Data & Analytics, a 2018 Emerging Pharma Leader by Pharmaceutical Executive, and a 2017 Top 40 Under 40 Leader in Minority Health by the National Minority Quality Forum (NMQF).
Boone holds, or has held, appointments to some of the most influential national committees focused on health data and patient centricity, including the Board of Directors for the Stewards of Change Institute, the Executive Board of Directors for the Patient Advocate Foundation, the Executive Board of Directors for the National Patient Advocate Foundation, the Board of Directors for SHARE for Cures, the Robert Wood Johnson Foundation’s Data Across Sectors for Health (DASH) Initiative, the Interoperability Committee for the National Quality Forum, the National Committee on Vital and Health Statistics (NCVHS) Working Group on HHS Data Access and Use, the Health IT Policy Committee (federal advisory committee), and the advisory group for the American Society of Clinical Oncologists’ (ASCO) CancerLinQ initiative.
Chris earned a B.S. from the University of Tulsa, a M.H.A. from the University of Texas at Arlington, a Ph.D. from the University of Texas at Dallas, and two executive certificates from the Harvard Kennedy School. He is a Fellow of the American College of Health Executives and a Fellow of the Healthcare Information Management & Systems Society.
Demetre C. Daskalakis, MD, MPH
Demetre C. Daskalakis, MD, MPH is the Deputy Commissioner for the Division of Disease Control at the NYC Department of Health and Mental Hygiene. Dr. Daskalakis directs the public health laboratory and all infectious disease control programs for NYC, including HIV, tuberculosis, sexually transmitted infections, vaccine-preventable diseases, and general communicable diseases. His division is among the largest in the Department, employing more than 1,100 staff, managing >$350 million, and operating 14 clinical facilities.
He received his medical education from the NYU School of Medicine and completed his residency training at Beth Israel Deaconess Medical Center in Boston. Dr. Daskalakis also completed clinical infectious disease fellowships at the Brigham and Women’s | Massachusetts General Hospital combined program and received a Master of Public Health from the Harvard T.H. Chan School of Public Health.
Dr. Daskalakis has focused much of his career on the treatment and prevention of HIV and other STIs as an activist physician with a focus on LGBTQIA+ communities. He was integral in designing and leading NYC’s Ending the Epidemic program, credited with decreasing HIV incidence to a historic low. In addition to his contributions to sexual health, Dr. Daskalakis has served as the Health Department’s incident commander during the measles outbreak of 2018-2019 as well as the current COVID-19 public health emergency.
Jason LaBonte is the Chief Strategy Officer at Datavant, a technology company powering the connection of healthcare data via privacy-protecting record linkage. Healthcare organizations use Datavant’s technology to safely share data to power better analysis, in turn leading to cost savings and better patient outcomes. At Datavant, Jason leads strategy and identifies ways to use the open data ecosystem to improve health care.
Jason joined Datavant with extensive experience in the healthcare data space, including executive roles at Decision Resources Group, MedPanel, and UPK, where he successfully designed and launched new products. Prior to that, Jason completed a Ph.D. in Virology at Harvard University and an A.B. in Molecular Biology at Princeton.